Evidence map›Paper›PMID 39430843›Full record

ArticleTranslational cancer research2024

Unveiling the role of

Xuebin Wan, Xiaoni Zhang, Mingyan Xu, Zhi Zheng, Yujun Zhou, Zhiyong Zhong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. UnlockingCurrent oncology (Toronto, Ont.) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xuebin Wan *Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID https://orcid.org/0000-0003-3276-1042
Xiaoni Zhang *HaploX Biotechnology, Co., Ltd., Shenzhen, China.
Mingyan Xu *HaploX Biotechnology, Co., Ltd., Shenzhen, China.
Zhi ZhengHaploX Biotechnology, Co., Ltd., Shenzhen, China.
Yujun ZhouHaploX Biotechnology, Co., Ltd., Shenzhen, China.
Zhiyong ZhongState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: One of the main challenges associated with the development of therapeutic and diagnostic strategies for patients with colorectal cancer (CRC) is the establishment of minimally invasive and efficient biomarkers. Pertinent genes in CRC have been identified through their functions in systematic mutagenesis screens. Methods: Sequencing data of 94 Chinese patients with CRC were prospectively collected and analyzed using next-generation sequencing (NGS). The influence of Results: The gene mutation rates of Conclusions: The TMB driven by

Indexed as

colorectal cancer (CRC)immune checkpoint inhibitors (ICIs)KRASmutant subtypestumor mutational burden (TMB)

Identifiers

PMID39430843
PMCPMC11483435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.